Metastatic Colorectal Cancer: Part 2 - Episode 10
Would you consider re-initiating bevacizumab in patients like Diane with multiple lines of treatment?
Cathy Eng, MD, FACP, The University of Texas MD Anderson Cancer Center, says the role of continued bevacizumab with further lines of therapy has not been evaluated beyond second-line treatment. There’s a benefit in the first-line setting, and it can be continued within the second-line setting. Beyond that, there is no literature to support it. Given the cost of the drug, it would be best utilized for only the first and second-line setting. Then, the focus must be brought to other therapies or participation in a clinical trial.
CASE: Metastatic Colorectal Cancer (Part 2)
Following her first-line recurrence, Diane is switched to FOLFIRI, and bevacizumab is continued.
In July of 2014, she presents to her oncologist with fatigue, dyspnea, and worsening performance status, and her CEA had increased to 180 ng/mL.
Based on results of her mutational analysis, which showed KRAS WT; BRAF negative; RAS WT, the patient is considered eligible for treatment with an anti-EGFR agent, and she is initiated on cetuximab + irinotecan.
In November of 2014, the patient presents with dyspnea, increasing CEA and worsening performance status.